Keros Therapeutics, Inc. (NASDAQ:KROS) Director Sells $11,002,500.00 in Stock

Keros Therapeutics, Inc. (NASDAQ:KROS) Director Carl L. Gordon sold 250,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $44.01, for a total transaction of $11,002,500.00. Following the completion of the sale, the director now directly owns 119,522 shares in the company, valued at $5,260,163.22. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Keros Therapeutics Trading Down 1.1 %

Shares of KROS stock opened at $45.54 on Friday. The company has a market cap of $1.64 billion, a PE ratio of -8.84 and a beta of 1.23. The company’s fifty day simple moving average is $46.84 and its 200-day simple moving average is $54.69. Keros Therapeutics, Inc. has a 52 week low of $27.02 and a 52 week high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.02). The company had revenue of $0.04 million during the quarter. During the same period in the prior year, the company posted ($1.27) earnings per share. Equities research analysts expect that Keros Therapeutics, Inc. will post -4.8 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on KROS. Oppenheimer started coverage on shares of Keros Therapeutics in a research note on Tuesday, June 25th. They set an “outperform” rating and a $102.00 price target on the stock. Truist Financial reaffirmed a “buy” rating and issued a $100.00 target price on shares of Keros Therapeutics in a research report on Tuesday, June 18th. Finally, HC Wainwright reissued a “buy” rating and set a $100.00 price target on shares of Keros Therapeutics in a research report on Tuesday, June 18th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $92.17.

Institutional Investors Weigh In On Keros Therapeutics

A number of large investors have recently modified their holdings of the stock. ADAR1 Capital Management LLC acquired a new position in Keros Therapeutics during the 4th quarter worth approximately $27,367,000. Redmile Group LLC purchased a new position in shares of Keros Therapeutics in the first quarter valued at $36,576,000. Darwin Global Management Ltd. grew its holdings in Keros Therapeutics by 35.4% during the 1st quarter. Darwin Global Management Ltd. now owns 1,435,950 shares of the company’s stock valued at $95,060,000 after purchasing an additional 375,523 shares in the last quarter. Franklin Resources Inc. increased its stake in Keros Therapeutics by 47.9% during the 4th quarter. Franklin Resources Inc. now owns 699,425 shares of the company’s stock worth $27,809,000 after buying an additional 226,674 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its holdings in Keros Therapeutics by 17.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,218,504 shares of the company’s stock worth $80,666,000 after buying an additional 176,803 shares in the last quarter. Institutional investors and hedge funds own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.